IMAGIN MEDICAL

enCAGE Precision Ablation System for Prostate Cancer

Precisely Targets Malignant Cells
While Preserving Delicate Structures

Q1 2024

Forward-Looking Statements

These materials may contain forward-looking statements relating to the business of Imagin Medical (the “Company” or “Imagin”) including with respect to the progress, timing and completion of the Company’s research, development, and clinical trials for product candidates, the Company’s ability to manufacture, market, commercialize, partner and achieve market acceptance for product candidates, its ability to protect its intellectual property and operate its business without infringing on the intellectual property rights of others, the Company’s estimates for future performance and its estimates regarding anticipated operating losses, future revenues, capital requirements, and its needs for additional financing, and any M&A timelines. Even if the Company’s actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the Company’s results or developments in the future. In some cases, you can identify forward-looking statements by words such as “could”, “should”, “may”, “expect”, “anticipates”, “believes”, “intends”, “estimates”, or similar words. These forward-looking statements are based largely on the Company’s current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance or achievements express or implied by these forward-looking statements. In particular, the Company’s expectations could be affected by, among other things, uncertainties involved in the development and manufacture of medical devices, unexpected results, unexpected regulatory actions or delays, competition in general, the Company’s ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will, in fact, be realized, and no representation or warranty is given as to the completeness or accuracy of the forward-looking statements contain in these materials.

Imagin is providing the information in these materials as of this date, and we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Imagin Medical* Business Overview

Prostate Cancer

- Innovative product dramatically improves targeting & safety of prostate cancer treatment
- $1B addressable market / 510(k) approved
- Successful initial results & 42-month follow-up of Clinical Study significantly mitigates market & regulatory risks
- Potential conversion of many prostatectomies to enCAGE may increase procedure market size
- 8 issued patents
- Management team with a successful track record

* Imagin Medical, Inc. is a development stage company with one 510(k) and does not currently have any other Medical Device Regulatory Approvals or Clearances to market products in any jurisdiction.



Imagin* Business Overview

Management Team

Jim Hutchens *President & CEO*	Boston Scientific	Smith+Nephew	**Venture Capital Early-Stage**
Stephen Sandler *Financial Advisor*	KPMG	VMARK	**Private Aviation Software**
Mike Vergano *Director of Operations*	Boston Scientific	**Corning Diagnostic**	**Microsurge** (all phases of project management)
Sheila Heyer, JD. *CFO, QA/RA, Consultant*	Boston Scientific	FDA	

World Class Medical Advisors & SAB

University College London
Mark Emberton, MD, *Dean of Faculty, Professor of Interventional Oncology, 500 peer reviewed papers, leading focal therapy proponent*

Clement Orczyk, *Professor of Urology. Department of Targeted Interventional Surgery & Interventional Science. Clinical lead diagnostic and focal therapy team for prostate cancer.*

NYU Langone Medical Center
Samir S. Taneja, MD, *Professor, Urologic Oncology, Radiology, Director, Division of Urologic Oncology. Clinical research focused on imaging in risk stratification and prostate cancer therapy. He has authored over 250 articles, 25 book chapters, and six textbooks.*

* Imagin Medical, Inc. is a development stage company and does not currently have any Medical Device Regulatory Approvals or Clearances to market products in any jurisdiction.

IMAGIN MEDICAL

Prostate Cancer – Most Prevalent Cancer in Men in the U.S.

Addressable Market

Total Global Market
$957,200,000

US Market
$452,400,000 enCAGE
+
$26,250,000 Generator
$478,650,000

+

International Market Equal to U.S. Market
$478,650,000

- ✓ # 2 in cancer deaths for men, 34.7K/year
- ✓ 1 out of 7 men will be diagnosed with prostate cancer, 3.1M living with prostate cancer
- ✓ 268K new cases/year
- ✓ High risk of damage to delicate structures during procedures procedures from procedures

IMAGIN MEDICAL

Today's Challenges

- Important nerves immediately adjacent to tumors can be damaged during every current treatment modality
- Difficulty in preventing damage to vulnerable tissue & structures beyond the margins of the tumor
- Erectile dysfunction and urinary incontinence are frequent side effects in these modalities
- Increased costs to the healthcare system

Today's Standards of Care

SURGERY

93,000
procedures

RADIATION

160,000
procedures



FOCAL THERAPY

Emerging
market

Prostate Market Trends

Movement to MIS Focal Therapy Procedures – enCAGE Will Dominate

The New Standard of Care: enCAGE Therapy

- enCAGE Coil creates a Faraday Cage effect “walling off” the delicate structures
- Radio Frequency (RF) energy within the coil targets only the tumor
- Erectile & urinary function damage minimized
- Minimizes future costs to the healthcare system

Faraday Cage Effect

enCAGE Control



enCAGE Coil Disposable Kit & Generator

Electrodes, Introducer and Guide Template

enCAGE Coil Electrode

8mm, 10mm, 12mm & 14mm

Introducer

Enables better targeting of electrode

Guide Template



Facilitates movement of electrode from ablation to ablation

Works with…

Imagin enCAGE RF Generator



Automated control based on impedance monitoring

**Works with commercially available Navigation Systems*

Imagin enCAGE Coil Clinical Peer Reviewed Study

20 patients were evaluated at University College London. Mark Emberton M.D. & Clement Orczyk M.D. A prototype device was used, and the clinical data was still excellent.

Following is an excerpt from an editorial comment in the peer reviewed *The Journal of Urology*:

"Coil RFA with the enCAGE device is a unique option for focal prostate ablation. With transperineal insertion, and ablation limited to the coil cage, treatments can be applied to both anterior and posterior lesions with minimal chance of ablating nearby vital structures.

EXCELLENT 42 MONTH FOLLOW-UP

"In this series of 20 men with intermediate risk prostate cancer, no grade 3-5 adverse events were reported, and 15 men had complete absence of any cancer at the 6-month biopsy. This is impressive considering that it was the first of its kind experience and post-treatment biopsy was mandated and thorough, with a median of 6 cores from the treatment site, which is beyond the approach of most focal therapy series. The success may in large part be due to the ingenious approach of adding extra needles to pull the energy outside the coil…"

* Results published in AUA Journal of Urology, April 2021.

IMAGIN MEDICAL

enCAGE Coil FDA Strategy

FDA Status

- 510(k) clearance for general soft tissue ablation
- Tissue ablation, as a specific indication for prostate ablation requires FDA clearance under Class 11 De Novo
- Pre-Submission meeting with FDA, approved enCAGE DeNovo clinical study plan

FDA Additional Action

- Submit Special 510(k) for refined enCAGE device for soft tissue indication
- Submit formal applications for prostate labeling when verification testing is complete

Final Development, Commercialization Timeline

Commercialized 5 Quarters After Receipt of Funding

	Year 1				Year 2			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
enCAGE Coil & RF Generator Development / Refinement								
enCAGE Coil & RF Generator Design / Beta Units								
Validation Testing								
FDA Special 510(k) approval process – soft tissue ablation DeNovo approval process – prostate tissue ablation					✓ Soft Tissue Commercialization			✓ Prostate Ablation Label

IMAGIN MEDICAL

Appendix

i/Blue™ Imaging System
for Bladder Cancer – Next Program



Bladder Cancer - i/Blue™ Imaging System

Addressable Market

Total Global Market
$678,000,000

US Market

$333,000,000 **Disposable**

$6,000,000 **Capital**

$339,000,000 **TOTAL**

+

International Market
Equal to U.S. Market
$339,000,000

- > 50% recurrence rate in non-muscle
- > 724,000 living in fear of recurrence
- 81,190 new cases/year; 17,240 deaths

Bladder cancer is the **6th most prevalent** cancer in the U.S.

Most expensive cancer to treat

IMAGIN MEDICAL

Current Systems vs. Imagin i/Blue

Corrects Limitations of Today's Blue Light

Current
Blue Light Equipment

VS

i/Blue
Imaging System



Exceptional Clinical & Economic Value Proposition

- Enables physician to **view two images on one screen** vs having to switch back and forth, improving clinical results
- i/Blue **miniaturizes and consolidates** 3 key components into one state-of-the-art optical system
- Leads to significantly **reduced manufacturing costs** leading to higher margins
- **i/Blue works with scopes already owned by the hospital** seamlessly into work protocol, and adds additional saving

Thank You!

CONTACT INFORMATION:

Jim Hutchens
President & CEO
(617) 571-6006
jhutchens@imaginmedical.com